@haanenjohn.bsky.social
Reposted
Cases of kidney cancer projected to double by 2050 globally due to modifiable risk factors.
From Alexander Kutikov, MD, FACS, et al
ascopost.com/news/october...
From Alexander Kutikov, MD, FACS, et al
ascopost.com/news/october...
Kidney Cancer Cases Expected to Double by 2050
A recent review tracked and projected the future global epidemiology of kidney cancer, examining its incidence, mortality, survival, genetic predisposition, and risk factors.
ascopost.com
October 8, 2025 at 5:16 PM
Cases of kidney cancer projected to double by 2050 globally due to modifiable risk factors.
From Alexander Kutikov, MD, FACS, et al
ascopost.com/news/october...
From Alexander Kutikov, MD, FACS, et al
ascopost.com/news/october...
Reposted
Review @natrevneph.nature.com @haanenjohn.bsky.social
Immunological features of clear-cell renal-cell carcinoma and resistance to immune checkpoint inhibitors
www.nature.com/articles/s41...
Immunological features of clear-cell renal-cell carcinoma and resistance to immune checkpoint inhibitors
www.nature.com/articles/s41...
Immunological features of clear-cell renal-cell carcinoma and resistance to immune checkpoint inhibitors - Nature Reviews Nephrology
Although immune checkpoint inhibitors can prolong survival in people with clear-cell renal-cell carcinoma, disease progression is frequent. Here, the authors explore potential mechanisms that might dr...
www.nature.com
July 22, 2025 at 8:38 PM
Review @natrevneph.nature.com @haanenjohn.bsky.social
Immunological features of clear-cell renal-cell carcinoma and resistance to immune checkpoint inhibitors
www.nature.com/articles/s41...
Immunological features of clear-cell renal-cell carcinoma and resistance to immune checkpoint inhibitors
www.nature.com/articles/s41...
Reposted
Researchers Veer Keizer and @riklindeboom.bsky.social have both received a Veni grant from the Dutch Research Council to set up and strengthen their own independent research lines ➡️
www.nki.nl/news-events/...
www.nki.nl/news-events/...
August 13, 2025 at 9:54 AM
Researchers Veer Keizer and @riklindeboom.bsky.social have both received a Veni grant from the Dutch Research Council to set up and strengthen their own independent research lines ➡️
www.nki.nl/news-events/...
www.nki.nl/news-events/...
Reposted
The May issue is live nature.com/nbt/volumes/...
On the cover, a ‘green’ platform for template-independent enzymatic synthesis of RNA oligonucleotides using reversible terminator nucleoside triphosphates that offers a sustainable alternative to traditional chemical methods go.nature.com/3zBfDZf
On the cover, a ‘green’ platform for template-independent enzymatic synthesis of RNA oligonucleotides using reversible terminator nucleoside triphosphates that offers a sustainable alternative to traditional chemical methods go.nature.com/3zBfDZf
May 17, 2025 at 8:21 PM
The May issue is live nature.com/nbt/volumes/...
On the cover, a ‘green’ platform for template-independent enzymatic synthesis of RNA oligonucleotides using reversible terminator nucleoside triphosphates that offers a sustainable alternative to traditional chemical methods go.nature.com/3zBfDZf
On the cover, a ‘green’ platform for template-independent enzymatic synthesis of RNA oligonucleotides using reversible terminator nucleoside triphosphates that offers a sustainable alternative to traditional chemical methods go.nature.com/3zBfDZf
Reposted
Promising results from Ph 1 trial of autologous PRAME-directed TCR-T cell therapy in HLA-A*02+ patients with PRAME+ recurrent and/or refractory solid tumors.
Out now in @naturemedicine.bsky.social!
Enrolment for Ph 3 trial of IMA203 ongoing 👇
clinicaltrials.gov/study/NCT067...
Out now in @naturemedicine.bsky.social!
Enrolment for Ph 3 trial of IMA203 ongoing 👇
clinicaltrials.gov/study/NCT067...
April 9, 2025 at 5:51 PM
Promising results from Ph 1 trial of autologous PRAME-directed TCR-T cell therapy in HLA-A*02+ patients with PRAME+ recurrent and/or refractory solid tumors.
Out now in @naturemedicine.bsky.social!
Enrolment for Ph 3 trial of IMA203 ongoing 👇
clinicaltrials.gov/study/NCT067...
Out now in @naturemedicine.bsky.social!
Enrolment for Ph 3 trial of IMA203 ongoing 👇
clinicaltrials.gov/study/NCT067...
Reposted
In the fight against bacterial pathogens, researchers are combining vaccination with targeted colonisation of the intestine by harmless microorganisms. This approach could potentially mark a turning point in the antibiotics crisis.
ethz.ch/en/news-and-...
ethz.ch/en/news-and-...
New vaccine concept tackles harmful bacteria in the intestine
In the fight against bacterial pathogens, researchers are combining vaccination with targeted colonisation of the intestine by harmless microorganisms. This approach could potentially mark a turning p...
ethz.ch
April 4, 2025 at 4:36 AM
In the fight against bacterial pathogens, researchers are combining vaccination with targeted colonisation of the intestine by harmless microorganisms. This approach could potentially mark a turning point in the antibiotics crisis.
ethz.ch/en/news-and-...
ethz.ch/en/news-and-...
Reposted
Check out this insightful animation from @vanrheenenlab.bsky.social @oncodeinstitute.bsky.social visualizing the findings of their recent Nature paper on tumor formation in the breast
Paper ➡️ www.nature.com/articles/s41...
More on the paper ➡️ www.nki.nl/news-events/...
#cancerresearch
Paper ➡️ www.nature.com/articles/s41...
More on the paper ➡️ www.nki.nl/news-events/...
#cancerresearch
Field cancerization
YouTube video by Antoni van Leeuwenhoek
youtu.be
April 4, 2025 at 12:34 PM
Check out this insightful animation from @vanrheenenlab.bsky.social @oncodeinstitute.bsky.social visualizing the findings of their recent Nature paper on tumor formation in the breast
Paper ➡️ www.nature.com/articles/s41...
More on the paper ➡️ www.nki.nl/news-events/...
#cancerresearch
Paper ➡️ www.nature.com/articles/s41...
More on the paper ➡️ www.nki.nl/news-events/...
#cancerresearch
Reposted
New study shows that neoadjuvant durvalumab + chemotherapy could improve outcomes for high-risk upper tract urothelial carcinoma. Explore the latest findings and implications for #oncology practice. ascopost.com/news/april-2... #ASCO2025 #CancerResearch #UrothelialCarcinoma
April 4, 2025 at 3:00 PM
New study shows that neoadjuvant durvalumab + chemotherapy could improve outcomes for high-risk upper tract urothelial carcinoma. Explore the latest findings and implications for #oncology practice. ascopost.com/news/april-2... #ASCO2025 #CancerResearch #UrothelialCarcinoma
Reposted
Neoadjuvant combination immunotherapy may improve treatment response in head and neck cancer. Using two immunotherapy drugs shows better tumor shrinkage and survival benefits compared to single-agent therapy. ascopost.com/news/march-2...
March 17, 2025 at 3:40 PM
Neoadjuvant combination immunotherapy may improve treatment response in head and neck cancer. Using two immunotherapy drugs shows better tumor shrinkage and survival benefits compared to single-agent therapy. ascopost.com/news/march-2...
Reposted
UK 🇬🇧 contingent at #SITCSpringScientific25!
What a stimulating meeting - fully dedicated to discussing everything cell therapy for solid tumours. Fantastic faculty & programme + excellent venue!
Feeling super inspired! 🌟
Thank you @sitcancer.bsky.social & the organisers!
@maxjulve.bsky.social
What a stimulating meeting - fully dedicated to discussing everything cell therapy for solid tumours. Fantastic faculty & programme + excellent venue!
Feeling super inspired! 🌟
Thank you @sitcancer.bsky.social & the organisers!
@maxjulve.bsky.social
March 14, 2025 at 10:06 PM
UK 🇬🇧 contingent at #SITCSpringScientific25!
What a stimulating meeting - fully dedicated to discussing everything cell therapy for solid tumours. Fantastic faculty & programme + excellent venue!
Feeling super inspired! 🌟
Thank you @sitcancer.bsky.social & the organisers!
@maxjulve.bsky.social
What a stimulating meeting - fully dedicated to discussing everything cell therapy for solid tumours. Fantastic faculty & programme + excellent venue!
Feeling super inspired! 🌟
Thank you @sitcancer.bsky.social & the organisers!
@maxjulve.bsky.social
Reposted
Excited to be here in San Diego 🇺🇸 for #SITCSpringScientific25 focussing on cellular therapy for solid tumours.
🚀 To kickstart, we hear keynote from @haanenjohn.bsky.social @nkinl.bsky.social sharing experience from academia-led work on TILs - from basic to translational research to clinical trials!
🚀 To kickstart, we hear keynote from @haanenjohn.bsky.social @nkinl.bsky.social sharing experience from academia-led work on TILs - from basic to translational research to clinical trials!
March 12, 2025 at 8:49 PM
Excited to be here in San Diego 🇺🇸 for #SITCSpringScientific25 focussing on cellular therapy for solid tumours.
🚀 To kickstart, we hear keynote from @haanenjohn.bsky.social @nkinl.bsky.social sharing experience from academia-led work on TILs - from basic to translational research to clinical trials!
🚀 To kickstart, we hear keynote from @haanenjohn.bsky.social @nkinl.bsky.social sharing experience from academia-led work on TILs - from basic to translational research to clinical trials!
Reposted
It’s gotten so bad we need a CHART to follow the whiplash firings and re-hirings 🤦🏻♂️
Who runs a company like this. Much less a country ??
Who runs a company like this. Much less a country ??
March 7, 2025 at 2:01 AM
It’s gotten so bad we need a CHART to follow the whiplash firings and re-hirings 🤦🏻♂️
Who runs a company like this. Much less a country ??
Who runs a company like this. Much less a country ??
Reposted
🌏 Our mission is guided by the C.A.R.E. model, focusing on transforming cancer care in underserved communities globally, implementing accessible care and empowering healthcare professionals. 💪 Learn more: buff.ly/3EtUOkY #cancer #nonprofit #CancerAwareness #oncology #healthcare #globalhealth
February 7, 2025 at 11:44 PM
🌏 Our mission is guided by the C.A.R.E. model, focusing on transforming cancer care in underserved communities globally, implementing accessible care and empowering healthcare professionals. 💪 Learn more: buff.ly/3EtUOkY #cancer #nonprofit #CancerAwareness #oncology #healthcare #globalhealth
Reposted
New: The largest medical A.I. randomized controlled trial yet performed, enrolling >100,000 women undergoing mammography screening
The use of AI led to 29% higher detection of cancer, no increase of false positives, and reduced workload compared with radiologists w/o AI thelancet.com/journals/lan...
The use of AI led to 29% higher detection of cancer, no increase of false positives, and reduced workload compared with radiologists w/o AI thelancet.com/journals/lan...
Screening performance and characteristics of breast cancer detected in the Mammography Screening with Artificial Intelligence trial (MASAI): a randomised, controlled, parallel-group, non-inferiority, ...
The findings suggest that AI contributes to the early detection of clinically relevant
breast cancer and reduces screen-reading workload without increasing false positives.
thelancet.com
February 4, 2025 at 3:00 AM
New: The largest medical A.I. randomized controlled trial yet performed, enrolling >100,000 women undergoing mammography screening
The use of AI led to 29% higher detection of cancer, no increase of false positives, and reduced workload compared with radiologists w/o AI thelancet.com/journals/lan...
The use of AI led to 29% higher detection of cancer, no increase of false positives, and reduced workload compared with radiologists w/o AI thelancet.com/journals/lan...
Reposted
Do check out our review on #celltherapy toxicities in solid cancers out now on #ESMO IO tech!
📚 Our review on the management of toxicities of cell therapy for solid cancers is now out in print in #ESMO ‘s flagship IO journal ESMO IOTECH.
👉 incl. TILs, TCR-T & CAR-T + associated tx e.g. IL-2 & NMA-LD.
🔗 www.esmoiotech.org/article/S259...
@sophiawongyn.bsky.social
@fbmh-uom.bsky.social
👉 incl. TILs, TCR-T & CAR-T + associated tx e.g. IL-2 & NMA-LD.
🔗 www.esmoiotech.org/article/S259...
@sophiawongyn.bsky.social
@fbmh-uom.bsky.social
January 4, 2025 at 10:32 AM
Do check out our review on #celltherapy toxicities in solid cancers out now on #ESMO IO tech!
Reposted
Great to see this out @naturemedicine.bsky.social! Exemplar translational research: autologous T cells (blood), expanded to predicted neoAg (Class I+II).
Congratulations @haanenjohn.bsky.social, @sklobuch.bsky.social & team @nkinl.bsky.social for once again advancing #CellTherapy in solid cancers.
Congratulations @haanenjohn.bsky.social, @sklobuch.bsky.social & team @nkinl.bsky.social for once again advancing #CellTherapy in solid cancers.
Just published: Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial
rdcu.be/d5ptS
rdcu.be/d5ptS
Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial
Nature Medicine - In this phase 1 trial of a personalized, neoantigen-specific autologous T cell therapy, BNT221, when given as monotherapy in patients with metastatic melanoma refractory to PD-1...
rdcu.be
January 3, 2025 at 4:31 PM
Great to see this out @naturemedicine.bsky.social! Exemplar translational research: autologous T cells (blood), expanded to predicted neoAg (Class I+II).
Congratulations @haanenjohn.bsky.social, @sklobuch.bsky.social & team @nkinl.bsky.social for once again advancing #CellTherapy in solid cancers.
Congratulations @haanenjohn.bsky.social, @sklobuch.bsky.social & team @nkinl.bsky.social for once again advancing #CellTherapy in solid cancers.
Reposted
Can patterns of progression on IO, inform future decisions?
-1377pts from 5 ph 3 trials used to create 3 PD risk levels
- low (⬆️existing lesions), intermediate (new lesions), high (both)
- risk score assoc w post-PD OS across tumors
Prognostic, so far #LCSM
jamanetwork.com/journals/jam...
-1377pts from 5 ph 3 trials used to create 3 PD risk levels
- low (⬆️existing lesions), intermediate (new lesions), high (both)
- risk score assoc w post-PD OS across tumors
Prognostic, so far #LCSM
jamanetwork.com/journals/jam...
Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy
This study examines a modified progressive disease classification and its association with postprogression survival in patients treated with atezolizumab across various solid tumors.
jamanetwork.com
December 26, 2024 at 8:55 PM
Can patterns of progression on IO, inform future decisions?
-1377pts from 5 ph 3 trials used to create 3 PD risk levels
- low (⬆️existing lesions), intermediate (new lesions), high (both)
- risk score assoc w post-PD OS across tumors
Prognostic, so far #LCSM
jamanetwork.com/journals/jam...
-1377pts from 5 ph 3 trials used to create 3 PD risk levels
- low (⬆️existing lesions), intermediate (new lesions), high (both)
- risk score assoc w post-PD OS across tumors
Prognostic, so far #LCSM
jamanetwork.com/journals/jam...
Reposted
Very proud of my 'partner-in-crime' 🙌 for showcasing our #MANIFESTuk consortium publicly for the first time at #ESMOImmuno24. Go @zaydtippu.bsky.social - you are a star! 🌟
Excited to get going with delivery in 2025!
@crick.ac.uk
@icrlondon.bsky.social
@cruk-mi.bsky.social
@mcrcnews.bsky.social
Excited to get going with delivery in 2025!
@crick.ac.uk
@icrlondon.bsky.social
@cruk-mi.bsky.social
@mcrcnews.bsky.social
December 13, 2024 at 11:52 AM
Very proud of my 'partner-in-crime' 🙌 for showcasing our #MANIFESTuk consortium publicly for the first time at #ESMOImmuno24. Go @zaydtippu.bsky.social - you are a star! 🌟
Excited to get going with delivery in 2025!
@crick.ac.uk
@icrlondon.bsky.social
@cruk-mi.bsky.social
@mcrcnews.bsky.social
Excited to get going with delivery in 2025!
@crick.ac.uk
@icrlondon.bsky.social
@cruk-mi.bsky.social
@mcrcnews.bsky.social
Reposted
New research shows younger and middle-aged adults have worse long COVID symptoms than older adults
"On an average of 10 months after COVID-19 onset, younger (ages 18-44) and middle-aged (ages 45-64) adults had worse neurologic symptoms of long COVID than adults 65 and older."
#LongCOVID
"On an average of 10 months after COVID-19 onset, younger (ages 18-44) and middle-aged (ages 45-64) adults had worse neurologic symptoms of long COVID than adults 65 and older."
#LongCOVID
New research shows younger and middle-aged adults have worse long COVID symptoms than older adults
New study from Northwestern Medicine finds symptoms occurred regardless of mild or severe COVID-19 infection
news.nm.org
November 22, 2024 at 10:50 PM
New research shows younger and middle-aged adults have worse long COVID symptoms than older adults
"On an average of 10 months after COVID-19 onset, younger (ages 18-44) and middle-aged (ages 45-64) adults had worse neurologic symptoms of long COVID than adults 65 and older."
#LongCOVID
"On an average of 10 months after COVID-19 onset, younger (ages 18-44) and middle-aged (ages 45-64) adults had worse neurologic symptoms of long COVID than adults 65 and older."
#LongCOVID